Skip to main content
SpringerLink
Log in

Late-breaking clinical trials presented at the American Heart Association Congress in Chicago 2010

  • Clinical trial updates and hotline sessions
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Abstract

This article gives an overview on the late-breaking clinical trials in the field of cardiovascular medicine which were presented during the hotline sessions at the American Heart Association Congress, held in Chicago, USA, from 13 to 17th November 2010. The data have been presented by leading experts in the field with relevant positions in the trials. The summaries provided in the manuscript were generated from the oral presentations and the webcasts of the American Heart Association (Laufs in Clin Res Cardiol 97:1–11, 2008; Möllmann in Clin Res Cardiol 98:1–7, 2009). The following papers are discussed in alphabetical order: ACT, ADVANCE, ASCEND-HF, ASCOT-CRP, CLOSURE I, DEFINE, EMPHASIS-HF, GRAVITAS, P-OM3, RAFT, ROCKET-AF, SMART-AV, SYMPLICITY HTN-2, TELE-HF, TIM-HF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Abbreviations

AF:

Atrial fibrillation

BP:

Blood pressure

CETP:

Cholesteryl ester transfer protein

CHD:

Coronary heart disease

CNS:

Central nervous system

CRT:

Cardiac resynchronization therapy

CV:

Cardiovascular

DES:

Drug eluting stents

HDL:

High density lipoprotein

HR:

Hazard ratio

hs-CRP:

High-sensitivity C-reactive protein

HVAD:

HeartWare left ventricular assist device

ICD:

Implantable cardioverter-defibrillator

INR:

International normalized ratio

ITT:

Intention to treat

LDL:

Low density lipoprotein

MI:

Myocardial infarction

NYHA:

New York Heart Association

PFO:

Patent foramen ovale

PRU:

Platelet reactivity units

RDN:

Renal denervation

TIA:

Transient ischemic attack

References

  1. Laufs U, Nef H, Möllmann H, Custodis F, Böhm M (2008) Clinical trial updates and hotline sessions presented at the Scientific Session 2007 of the American Heart Association. Clin Res Cardiol 97(1):1–11

    Article  CAS  PubMed  Google Scholar 

  2. Möllmann H, Nef H, Böhm M, Laufs U (2009) Highlights of the hotline sessions presented at the scientific sessions 2008 of the American Heart Association. Clin Res Cardiol 98(1):1–7

    Article  PubMed  Google Scholar 

  3. Berwanger O (2010) Acetylcystein for the prevention of contrast-induced nephropathy (ACT) trial: a pragmatic multicenter randomized trial to evaluate the efficacy of acetylcysteine for the prevention of renal outcomes in patients undergoing coronary and vascular angiography. American Heart Association Scientific Sessions, November 16 2010, Chicago, IL (Late Breaking Clinical Trials III)

  4. Aaronson KD (2010) Evaluation of the HeartWare® HVAD left ventricular assist device system for bridge to tranaplant in advanced heart failure: the ADVANCE trial. American Heart Association 2010 Scientific Sessions; November 15, Chicago, IL. Late-Breaking Clinical Trials I

  5. Hernandez AF (2010) Acute study of clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF)—nesiritide or placebo for improved symptoms and outcomes in acute decompensated HF. American Heart Association 2010 Scientific Sessions, November 14 2010, Chicago, IL (Late-Breaking Clinical Trials I)

  6. Sever P (2010) The anglo-scandinavian cardiac outcomes trial (ASCOT): testing C-reactive protein at baseline and on-treatment as an independent predictor of cardiovascular outcomes. American Heart Association 2010 Scientific Sessions, November 17 2010, Chicago, IL (Late breaking clinical trials IV)

  7. Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New Engl J Med 359:2195–2207

    Article  CAS  PubMed  Google Scholar 

  8. Furlan A (2010) CLOSURE I: a prospective, multicenter, randomized, controlled trial to evaluate the safety and efficacy of the STARFLEX® septal closure system versus best medical therapy in patients with a stroke or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale. American Heart Association 2010 Scientific Sessions; November 15 2010, Chicago, IL (Late-breaking clinical trials II)

  9. Cannon CP, Shah S, Hayes MD et al (2010) Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. doi:10.1056/NEJMoa1009744

  10. Cannon CP (2010) Primary results of the DEFINE trial: determining the efficacy and tolerability of CETP inhibition with anacetrapid. American Heart Association 2010 Scientific Sessions, November 17 2010, Chicago, IL (Late-breaking clinical trials IV)

  11. Pöss J, Böhm M, Laufs U (2010) HDL im Rahmen der Atherogenese und HDL-Steigerung durch CETP-Inhibition. Dtsch Med Wochenschr 135:188–192

    Article  PubMed  Google Scholar 

  12. Zannad F (2010) The effect of eplerenone versus placebo on cardiovascular mortality or heart failure hospitalization in subjects with NYHA class II chronic systolic heart failure. EMPhASIS-HF. American Heart Association 2010 Scientific Sessions, November 14 2010, Chicago, IL (Late-breaking clinical trials I)

  13. Zannad F, McMurray JJ, Krum H et al (2010) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. doi 10.1056/NEJMoa1009492

  14. Price MJ, Berger PB et al (2009) Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J 157(5):818–824

    Article  CAS  PubMed  Google Scholar 

  15. Price MJ (2010) Standard versus high-dose clopidogrel according to platelet function testing after PCI: results of the GRAVITAS trial. American Heart Association 2010 Scientific Sessions, November 16 2010, Chicago, IL (Late-breaking clinical trials III)

  16. Kowey PR, Reiffel JA, Ellenbogen KA et al (2010) Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation. A randomized controlled trial. JAMA. doi:10.1001/jama.2010.1735

  17. Kowey PR (2010) Efficacy and safety of prescription omega-3-acid ethyl esters (P-OM3) for the prevention of recurrent symptomatic atrial fibrillation (AF). American Heart Association 2010 Scientific Sessions, November 15 2010, Chicago, IL (Late-breaking clinical trials II)

  18. Tang AS, Wells GA, Talajic M et al (2010) Cardiac-Resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. doi 10.1056/NEJMoa1009540

  19. Tang AS (2010) The resynchronization/defibrillation for ambulatory heart failure trial (RAFT). American Heart Association 2010 Scientific Sessions, November 14, Chicago, IL. (Late-breaking clinical trials I)

  20. Mahaffey K (2010) Stroke prevention using the oral direct factor Xa inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation (ROCKET AF). American Heart Association 2010 Scientific Sessions, November 15 2010, Chicago, IL (Late-breaking clinical trials II)

  21. Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151

    Article  CAS  PubMed  Google Scholar 

  22. Ellenbogen K, Gold M, Meyer T (2010) Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial. Circulation. doi:10.1161/CIRCULATIONAHA.110.992552

  23. Ellenbogen K (2010) Primary results from the SMART-AV trial: a randomized trial comparing empiric, echocardiographic guided and algorithmic AV delay programming in cardiac resynchronization therapy (CRT). American Heart Association 2010 Scientific Sessions, November 15 2010, Chicago, IL (Late-breaking clinical trials II)

  24. Lloyd-Jones D, Adams RJ, Brown TM et al (2010) Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 121:e46–e215

    Article  PubMed  Google Scholar 

  25. Wolf-Maier K, Cooper RS, Kramer H et al (2004) Hypertension treatment and control in five European countries, Canada and the United States. Hypertension 43:10–17

    Article  CAS  PubMed  Google Scholar 

  26. DiBona GF, Kopp UC (1997) Neural control of renal function. Physiol Rev 77:75–197

    CAS  PubMed  Google Scholar 

  27. Krum H et al (2009) Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373(9671):1275–1281 epub 2009 Mar 28

    Google Scholar 

  28. Symplicity HTN-2 Investigators (2010) Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. doi:10.1016/S0140-6736(10)62039-9

  29. Esler M (2010) SYMPLICITY HTN-2: international, multicenter, prospective, randomized, controlled trial of endovascular selective renal sympathetic denervation for the treatment of hypertension. American Heart Association 2010 Scientific Sessions, November 17 2010, Chicago, IL (Late-breaking clinical trials IV)

  30. Chaudhry SI, Mattera JA, Curtis JP et al (2010) Telemonitoring in patients with heart failure. N Engl J Med. doi:10.1056/NEJMoa1010029

  31. Chaudhry SI (2010) Telemonitoring to improve outcomes after heart failure hospitalization: a randomized clinical trial. American Heart Association 2010 Scientific Sessions, November 16 2010, Chicago, IL (Clinical science: special reports III)

  32. Anker SD (2010) Telemedical interventional monitoring in heart failure (TIM-HF), a randomized, controlled, intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with chronic heart failure. American Heart Association 2010 Scientific Sessions, November 16 2010, Chicago, IL (Clinical science: special reports III)

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin III, Kardiologie Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, 66421, Homburg/Saar, Germany

    Christoph Gensch, Uta Hoppe, Michael Böhm & Ulrich Laufs

  2. Klinik III für Innere Medizin, Herzzentrum der Universität zu Köln, Kerpener Str. 62, 50937, Cologne, Germany

    Uta Hoppe

Authors
  1. Christoph Gensch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Uta Hoppe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Böhm
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ulrich Laufs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christoph Gensch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gensch, C., Hoppe, U., Böhm, M. et al. Late-breaking clinical trials presented at the American Heart Association Congress in Chicago 2010. Clin Res Cardiol 100, 1–9 (2011). https://doi.org/10.1007/s00392-010-0270-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-010-0270-3

Keywords

Search

Navigation